Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase 1/2 2Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Breast Neoplasms 320Leukemia, Myeloid, Acute 266Multiple Myeloma 227Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 202Neoplasms 196Lymphoma 191Colorectal Neoplasms 184Melanoma 179Leukemia 170Recurrence 164Pancreatic Neoplasms 163Precursor Cell Lymphoblastic Leukemia-Lymphoma 160Lung Neoplasms 150Glioblastoma 134Neoplasm Metastasis 132Lymphoma, Non-Hodgkin 128Ovarian Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 120Myelodysplastic Syndromes 117Lymphoma, Large B-Cell, Diffuse 110Lymphoma, Mantle-Cell 108Carcinoma, Hepatocellular 103Lymphoma, Follicular 99Stomach Neoplasms 96Carcinoma, Renal Cell 89Hodgkin Disease 88Brain Neoplasms 88Sarcoma 84Burkitt Lymphoma 75

Interventions

pembrolizumab 1Surgery, Computer-Assisted 1Solutions 1Indocyanine Green 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Head and Neck Carcinoma × Clear all
NCT02718820 2024-01-09

Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer

Medical University of Vienna

Phase 1/2 Completed
22 enrolled 10 charts
Head & Neck

Head and Neck Carcinoma

NCT03745690 2022-03-17

Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Withdrawn
Head & Neck

Head and Neck Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡